AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $736 | +1.9% | 60,533 | +5.2% | 0.01% | 0.0% |
| Q2 2023 | $722 | +0.3% | 57,522 | -11.4% | 0.01% | 0.0% |
| Q1 2023 | $720 | -6.9% | 64,911 | +2.6% | 0.01% | -16.7% |
| Q4 2022 | $773 | -99.9% | 63,279 | -8.1% | 0.01% | +20.0% |
| Q3 2022 | $719,000 | +88.7% | 68,881 | +94.3% | 0.01% | +66.7% |
| Q2 2022 | $381,000 | -11.0% | 35,448 | -21.6% | 0.00% | +50.0% |
| Q1 2022 | $428,000 | -9.9% | 45,239 | +9.9% | 0.00% | 0.0% |
| Q4 2021 | $475,000 | +46.2% | 41,164 | +20.9% | 0.00% | 0.0% |
| Q3 2021 | $325,000 | +9.8% | 34,051 | +11.0% | 0.00% | 0.0% |
| Q2 2021 | $296,000 | +14.7% | 30,664 | +17.6% | 0.00% | +100.0% |
| Q1 2021 | $258,000 | -47.8% | 26,070 | +21.9% | 0.00% | -66.7% |
| Q4 2020 | $494,000 | +142.2% | 21,392 | +48.3% | 0.00% | +200.0% |
| Q3 2020 | $204,000 | -24.2% | 14,429 | -35.1% | 0.00% | -50.0% |
| Q3 2018 | $269,000 | -54.3% | 22,230 | -41.0% | 0.00% | -50.0% |
| Q2 2018 | $589,000 | -4.8% | 37,696 | -8.4% | 0.00% | 0.0% |
| Q1 2018 | $619,000 | -13.9% | 41,158 | -17.6% | 0.00% | -20.0% |
| Q4 2017 | $719,000 | +295.1% | 49,939 | +314.5% | 0.01% | +400.0% |
| Q3 2017 | $182,000 | +76.7% | 12,048 | +17.6% | 0.00% | 0.0% |
| Q2 2017 | $103,000 | +43.1% | 10,243 | +1.7% | 0.00% | 0.0% |
| Q1 2017 | $72,000 | +33.3% | 10,074 | -6.9% | 0.00% | – |
| Q4 2016 | $54,000 | -41.3% | 10,824 | -12.7% | 0.00% | -100.0% |
| Q3 2016 | $92,000 | +7.0% | 12,401 | -21.6% | 0.00% | 0.0% |
| Q2 2016 | $86,000 | -25.9% | 15,808 | +15.6% | 0.00% | 0.0% |
| Q1 2016 | $116,000 | +16.0% | 13,680 | +32.9% | 0.00% | 0.0% |
| Q4 2015 | $100,000 | -42.9% | 10,292 | -17.8% | 0.00% | 0.0% |
| Q3 2015 | $175,000 | +326.8% | 12,518 | +333.0% | 0.00% | – |
| Q2 2015 | $41,000 | +64.0% | 2,891 | +28.0% | 0.00% | – |
| Q1 2015 | $25,000 | +31.6% | 2,259 | +0.0% | 0.00% | – |
| Q4 2014 | $19,000 | – | 2,258 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |